SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

Manuela Mancini(Istituto di Ematologia di Bologna), Simona Soverini(University of Bologna)
Biomarker Research
March 9, 2023
10.1186/s40364-023-00468-7
Cited by 6

Related Papers

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
|Leukemia|2017|38
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
|Cancers|2022|2
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
|Research Square|2022|0